Keywords: fda, delays, review, lilly, sepsis, drug, food
FDA delays review of Lilly's sepsis drug
Article | 15 June 2001
The US Food and Drug Administration has unexpectedly delayed its reviewof Eli Lilly's sepsis treatment Xigris (drotrecogin alfa; formerly Zovant) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
